Progress in the study on innate immunity and non-alcohol fatty liver disease.
10.11817/j.issn.1672-7347.2020.190359
- Author:
Jingfeng LOU
1
;
Guangyu YAN
2
;
Zhijun HUANG
2
;
Hong YUAN
2
;
Yao LU
3
Author Information
1. Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha 410013, China. ljjingfdeng0928@163.com.
2. Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
3. Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha 410013, China. luyao0719@163.com.
- Publication Type:Journal Article
- Keywords:
innate immunity;
new therapeutic targets;
non-alcohol fatty liver disease;
treatment
- MeSH:
Humans;
Immunity, Innate;
Kupffer Cells;
Liver;
Non-alcoholic Fatty Liver Disease
- From:
Journal of Central South University(Medical Sciences)
2020;45(12):1464-1468
- CountryChina
- Language:English
-
Abstract:
The incidence of non-alcohol fatty liver disease (NAFLD) is increasing year by year, and the relevant cardiovascular events have become a major problem in chronic diseases management. The activation of innate immunity is closely related to the development of NAFLD. The immune cells include Kupffer cells, neutrophils, dendritic cells, and natural killer T cells, which acts through the activation of innate immunity-related signals mediated by pattern recognition receptors.
